AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02934386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WinMedical WinPack device
Study NCT04036227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-248
Description: GS-248 oral solution
Study NCT04036227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution with the same composition to match active drug
Study NCT02569840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Amino Acid Feed
Description: Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 2 mg
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 10 mg
Study NCT00906672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap technique
Description: A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
Study NCT04144673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Hydrosol
Description: Silver quantity will be 7 doses per day, with 50 mcg per dose.
Study NCT04144673 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo water with no active ingredients
Study NCT00982462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (ARA)
Description: Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 30 mg
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 100 mg
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 300 mg
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose 600 mg
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose - to be determined with food
Study NCT00982462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil placebo
Description: Micro-encapsulated powder containing corn oil as the placebo.
Study NCT04396067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid
Description: The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study NCT04396067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized All trans retinoic acid
Description: The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: Single Dose - to be determined
Study NCT01247896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose Placebo
Study NCT00271999 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal home hemodialysis
Description: Six times per week nocturnal home hemodialysis
Study NCT00271999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis
Description: Six times per week nocturnal home hemodialysis
Study NCT01521767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of extended release capsules
Study NCT01521767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: 4 mg single dose of microspheres in powder blend
Study NCT04396067 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a pill or tablet that does not contain any study drug.
Study NCT04681222 — intervention group
Intervention type: PROCEDURE
Intervention: LFCN
Description: LFCN block was performed in combination with PENG block
Study NCT04681222 — intervention group
Intervention type: PROCEDURE
Intervention: Wound infiltration
Description: Wound infiltration was performed in combination with PENG block
Study NCT02483481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: shear wave ultrasound elastography
Description: shear wave ultrasound elastography
Study NCT03931057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV6209 (=gamma-cyclodextrin-Midazolam)
Description: 30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
Study NCT03931057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
Study NCT00807625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Provera
Description: Depo Provera administered by injection at randomization visit and the 12-week study visit.
Study NCT00807625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T Intrauterine contraception device
Description: IUCD inserted upon randomization to this study arm
Study NCT00028730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00028730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00028730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00028730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00028730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00028730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00028730 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01406873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: 150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
Study NCT01406873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
Study NCT02619331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allergy test reading
Description: Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
Study NCT02077192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium
Description: Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
Study NCT03796299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of expression of MCM5 in the urine (ADX Bladder)
Description: Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
Study NCT01315483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Dietary Pattern
Description: Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
Study NCT01272193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
Study NCT01272193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
Study NCT01272193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT04644354 — intervention group
Intervention type: DRUG
Intervention: Nifedipine 10 mg
Description: For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
Study NCT03553459 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg Maneuver
Description: In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT01918709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH iontophoretic transdermal Lutrepatch
Description: 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Oral, 50 mg daily for 5 days
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo clomiphene citrate
Description: oral, taken for 5 days
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo GnRH patch
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Study NCT00796289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo GnRH patch
Description: Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Study NCT02118753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
Study NCT02464878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alpha 1-Antitrypsin
Description: Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
Study NCT02464878 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Islet Transplantation
Study NCT02464878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thymoglobulin
Description: Patients will receive a total of 5 doses between Day -2 and Day +2
Study NCT02464878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab
Description: Basiliximab will be used for subsequent transplants.
Study NCT02464878 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
Study NCT01682473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSTK474
Description: Two arms, each with serial cohorts receiving escalating doses.
Study NCT01805310 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bowel preparation
Description: Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
Study NCT01805310 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No bowel preparation
Description: Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
Study NCT03634332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
Study NCT03634332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
Study NCT01722266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards.
Study NCT01722266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards.
Study NCT02391883 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Study NCT01433133 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: implantation
Description: subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
Study NCT02059577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Interventions
Description: Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
Study NCT03292783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV1501 (ABL001)
Description: VEGF/DLL4 targeting bispecific antibody
Study NCT04421885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference
Description: 600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
Study NCT04421885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test
Description: 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
Study NCT01580020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFB002
Description: 0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
Study NCT01580020 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
Study NCT05958810 — intervention group
Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)
Study NCT05958810 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study NCT01212783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy
Description: Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
Study NCT01212783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy
Description: Present-Centered Therapy is a supportive psychotherapy.
Study NCT02280356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT02280356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT02280356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02524106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab
Description: PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Study NCT02524106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01754090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.
Study NCT01754090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.